IMUX expects pivotal Phase 3 vidofludimus calcium data by end-2026
IMUX is advancing vidofludimus calcium through pivotal Phase 3 trials in relapsing MS. Top-line data are expected by end of 2026, with a U.S. NDA submission targeted for mid-2027.
S. NDA submission targeted for mid-2027. The therapy's dual mechanism is intended to address both inflammation and neurodegeneration, with the aim of meeting significant unmet needs in relapsing MS.